Table 2. Relationship between patient characteristics and ALI.
| Baseline characteristic | ALI ≥22.2 | ALI <22.2 | p value | |
|---|---|---|---|---|
| n = 148 | n = 18 | |||
| Age (years) | <75 | 109 | 8 | 0.01 |
| ≥75 | 39 | 10 | ||
| Gender | Male | 82 | 10 | 0.99 |
| Female | 66 | 8 | ||
| Brinkman index | 0 | 80 | 9 | 0.839 |
| <600 | 32 | 5 | ||
| ≥600 | 36 | 4 | ||
| Performance status (ECOG) | 0 | 143 | 15 | <0.001 |
| 1 | 4 | 0 | ||
| 2 | 1 | 3 | ||
| Body Mass Index (kg/m2) | <18.5 | 9 | 6 | 0.001 |
| ≥18.5 to <25 | 101 | 10 | ||
| ≥25 | 38 | 2 | ||
| Hugh-Jones classification | 1 | 140 | 14 | 0.016 |
| 2 | 6 | 3 | ||
| 3 | 1 | 1 | ||
| Surgical procedure | Wedge resection | 18 | 4 | 0.49 |
| Segmentectomy | 26 | 3 | ||
| Lobectomy | 101 | 11 | ||
| Lymphatic permeation | Absent | 134 | 15 | 0.341 |
| Present | 14 | 3 | ||
| Vascular invasion | Absent | 132 | 14 | 0.16 |
| Present | 16 | 4 | ||
| T factor | 1 (mi) | 35 | 1 | 0.197 |
| (1a) | 31 | 7 | ||
| 2 (1b) | 50 | 6 | ||
| 3 (1c) | 32 | 4 | ||
| Pathological subtype | Minimally invasive Adenocarcinoma | 35 | 1 | 0.074 |
| Lepidic | 61 | 9 | ||
| Papillary | 35 | 3 | ||
| Acinar | 10 | 2 | ||
| Solid | 5 | 1 | ||
| Others | 2 | 2 | ||
| CEA (ng/mL) | ≤5 | 138 | 13 | 0.003 |
| >5 | 10 | 5 | ||
| CRP (mg/dL) | ≤1 | 147 | 13 | <0.001 |
| >1 | 1 | 5 | ||
| Albumin (g/dL) | ≥3.5 | 145 | 14 | <0.001 |
| <3.5 | 3 | 4 | ||
| GPS | 0 | 145 | 11 | <0.001 |
| 1 | 2 | 5 | ||
| 2 | 1 | 2 | ||
| RDW | <13.3 | 89 | 8 | 0.202 |
| ≥13.3 | 59 | 10 | ||
| PLR | <120 | 68 | 1 | 0.001 |
| ≥120 | 80 | 17 | ||
| NLR | <3.43 | 140 | 3 | <0.001 |
| ≥3.43 | 8 | 15 | ||
| %VC (%) | ≥80 | 137 | 13 | <0.001 |
| <80 | 7 | 5 | ||
| Not recorded | 4 | 0 | ||
| %FEV1.0 (%) | ≥80 | 119 | 17 | 0.198 |
| <80 | 25 | 1 | ||
| Not recorded | 4 | 0 | ||
| %DLCO (%) | ≥80 | 135 | 15 | 0.112 |
| <80 | 9 | 3 | ||
| Not recorded | 4 | 0 | ||
| Status | Alive | 132 | 9 | <0.001 |
| Dead | 16 | 9 | ||
| Cause of death | Cancer | 7 | 1 | 0.093 |
| Other disease | 9 | 8 | ||
ECOG: eastern cooperative oncology group; CEA: carcinoembryonic antigen; CRP: C-reactive protein; GPS: glasgow prognostic score; RDW: red cell distribution width; PLR: platelet-to-lymphocyte ratio; NLR: neutrophil-to-lymphocyte ratio; ALI: advanced lung cancer inflammation index; VC: vital capacity; FEV: forced expiratory volume; DLCO: diffusing capacity of lung carbon monoxide